This article is more than 5 years old. Information may no longer be current.
TREX-AMD study shows relationship of risk factors to macular atrophy
Click Here to Manage Email Alerts
SAN FRANCISCO — Subfoveal choroidal thickness and subretinal hyperreflective material thickness were risk factors statistically significantly related to macular atrophy in eyes with neovascular age-related macular degeneration, according to a study.
“But in eyes that had no macular atrophy at baseline, the presence of [subretinal hyperreflective material], the thickness of SHRM and the thickness of the [pigment epithelium detachment], and the presence of hemorrhage at baseline on color fundus photographs were all significant predictors of the new development, or the new occurrence, of atrophy along the 18 months of follow-up,” Nizar Abdelfattah, MD, said at the American Society of Retina Specialists annual meeting.
In the TREX-AMD study, 88 eyes were divided among monthly treatment (19 eyes), treat-and-extend treatment (30 eyes) and control (39 eyes).
The rate of macular atrophy was similar among all groups, but there was a larger trend in the treat-and-extend group.
“We also found that the prevalence of atrophy in the entire cohort was about 40% with the highest prevalence in the TREX group, and the incidence of macular atrophy was found to be highest in the monthly group receiving ranibizumab,” Abdelfattah said. – by Patricia Nale, ELS
Reference:
Abdelfattah N. Macular atrophy in neovascular age-related macular degeneration eyes treated with monthly or treat-and-extend ranibizumab: TREX-AMD Report No. 2. Presented at: American Society of Retina Specialists annual meeting; Aug. 9-14, 2016; San Francisco.
Disclosure: Abdelfattah reports no relevant financial disclosures.